Oruka trial data from the ongoing EVERLAST-B study of ORKA-001 is scheduled for release on October 26, 2026. Oruka Therapeutics said it will report Week 16 results from the Phase 2b trial in moderate-to-severe plaque psoriasis and discuss them on a conference call and webcast.

What the Oruka trial data will cover

The planned announcement concerns ORKA-001 in EVERLAST-B, an ongoing trial involving people with moderate-to-severe plaque psoriasis. The company announced the reporting date on October 25 but did not disclose the Week 16 results in that announcement.

Oruka is a clinical-stage biotechnology company developing biologics for chronic skin diseases, including plaque psoriasis and hidradenitis suppurativa.

Webcast scheduled after announcement

The results webcast is set to begin at 8:00 a.m. Eastern Time on October 26. It will be accessible through the investors section of Oruka’s website, and a replay will be available after the call.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.